Global endeavors to respond to the problems caused by climate change and are leading to higher temperatures inside homes, which can cause skin conditions (such as eczema), lethargy, and poor concentration; disturbed sleep and fatigue are also rising. The energy performance of buildings is influenced by interactions and associations of numerous different variables, such as the envelope specifications as well as the design, technologies, apparatuses, and occupant behaviours. This paper introduces simple and sustainable strategies that are not dependent on expensive or sophisticated technologies, as they rely only on the actions practiced by the building’s occupants (movable window shading, and nighttime natural ventilation) instead of completely relying on high-cost mechanical cooling systems in buildings located in the main Eastern Mediterranean climates represented in the country of Jordan. These low-energy solutions could be applied to low-income houses in hot areas to avoid health problems, such as dermatological diseases, and save a significant amount of energy. The final results indicate that window shading has significant potential in reducing the cooling load in different climate zones. Natural ventilation exhibits high energy-saving abilities in climates that have cool nights, whereas its abilities in hot climates where nights are moderate is limited.
21 February 2020 in Journal of Dermatological Treatment
Background: The pathogenesis of vitiligo is complex and multifactorial, accumulating evidence of increased oxidative stress and reduction in catalase levels in vitiligo patients has been shown, hence Pseudocatalase/superoxide dismutase (PSD) gel has been used as treatment option for vitiligo. Aim: To assesses the synergic effect of PSD when combines with Tacrolimus 0.1% ointment versus Tacrolimus 0/1% alone. Method: A randomized controlled trial that included 49 children with vitiligo with limited area (10% or less). Patients were randomized into 2 groups: Group 1(24 patients) were treated only with Tacrolimus 0.1% ointment whereas Group 2 (25 patients) were treated with Tacrolimus 0.1% ointment plus PSD. Degree of repigmentation compared to baseline was assessed at 3, 6 and 9 months. Results: The median age was 10.05 year (range; 2-18). The percentages of pigmentation on 3,6 and 9 months for group 1 were 23.9%, 40.4% and 60% respectively and for group 2 were 23.2%, 40.7% and 62.4% respectively. There was no significant difference according to repigmentation percentages between the two groups (p > 0.86, p > 0.97and p > 0.78 respectively). Conclusion: The results showed that the addition of PSD to Tacrolimus ointment in children with limited vitiligo was not associated with any therapeutic benefit.
1 November 2020 in Clinical, Cosmetic and Investigational Dermatology
Background: Alopecia areata (AA) usually manifests as patches of non-scarring hair loss due to immune dysregulation. Intradermal injection of steroids is considered a first-line treatment of patchy AA. Purpose: To compare the efficacy and safety of two commonly used concentrations of intralesional triamcinolone acetonide (ILT) (5 mg/mL vs 10 mg/mL) in the treatment of patchy AA on the scalp. Patients and Methods: A retrospective comparative study that included 85 patients diagnosed with patchy AA on the scalp, who were treated with monthly injections of ILT. Patients were divided into Group 1 that received 5 mg/mL and Group 2 that received 10 mg/mL. The response rate (defined as the percentage of patients who achieved complete hair regrowth) and the side effects were compared between the two groups after completion of three treatment sessions, and recurrence was assessed after 1− 3 years. Results: Demographic composition of the two groups was comparable. The difference in response rate and the side-effects between the two groups were not statistically significant. Complete hair regrowth was noted in 43.5% of patients in Group 1 and 53.8% of those in Group 2 (P=0.340). About 17% and 25% of patients in Group 1 and Group 2, respectively, developed minor local side-effects (P=0.354), and almost 45% of patients from both groups had recurrence after 1− 3 years. Disease duration exceeding 6 months correlated with poor treatment response. Conclusion: Intralesional injection of triamcinolone acetonide 5 mg/mL is equally effective and safe compared to 10 mg/mL in the treatment of patchy alopecia areata.
21 December 2023 in Journal of Dermatological Treatment
This study aims to assess the efficacy and safety of combining the 308-nm Excimer lamp with Tacrolimus 0.1% ointment, compared to Tacrolimus 0.1% ointment monotherapy, for treating pediatric vitiligo involving less than 10% of the body surface area. Fifty pediatric patients with vitiligo were randomly assigned to two groups. Group A received Tacrolimus 0.1% ointment twice daily and Excimer light at 308-nm twice weekly, while Group B received Tacrolimus 0.1% ointment alone, administered twice daily. Repigmentation percentages were evaluated after 30, 90, and 180 days using the rule of nine. Group A exhibited a significant improvement in repigmentation, increasing from 10% after one month to 65% after six months. In contrast, Group B observed an increase from 10% to 30% over the same timeframe. The efficacy of the treatment was significantly higher in Group A at both the 3-month and 6-month follow-up points (p-value < .001). Moreover, Group A achieved notably higher repigmentation rates in the face, trunk, and lower limbs. The combination of Tacrolimus and the 308-nm excimer lamp yielded superior repigmentation results compared to Tacrolimus monotherapy in pediatric vitiligo patients. This combined approach may offer an effective new treatment protocol for pediatric vitiligo.
12 May 2022 in Euro-Mediterranean Journal for Environmental Integration
Purpose: Vitiligo is an idiopathic depigmenting skin disorder. The study compares the efficacy of topical tacrolimus 0.1% with calcipotriol/betamethasone dipropionate in vitiligo patients receiving NB-UVB treatment.Materials and methods: Forty-one adult patients with generalized type vitiligo were recruited. Patients were assigned to phototherapy and then classified into either group one (20 patients), receiving calcipotriol/betamethasone dipropionate cream (D group), or group two (21 patients), receiving tacrolimus 0.1% ointment (T group). They were followed-up at 3 and 6 months.Results: The D group witnessed an increase in the repigmentation area from 35.4% in the third month to 54.7% in the sixth month (p = 0.001) and the T group from 32.2% to 45.6% (p = 0.011). However, the differences between the treatment groups were not statistically significant. Body sites demonstrated different levels of improvement ranging from the highest in the face to the lowest in the Hand & Feet with the other body sites in between. A negative correlation was identified between the duration since diagnosis and the response to D treatment (3 months: r = -0.612, p = 0.007; 6 months: r = -0.755, p = 0.001).Conclusions: Although both combinations are efficacious, they did not significantly differ in efficacy at three and six months follow-up points.Clinical trial registration: The study was registered at clinicaltrials.gov (NCT04440371).